View : 29 Download: 0
A prime determinant in selecting dialysis modality: Peritoneal dialysis patient survival
- A prime determinant in selecting dialysis modality: Peritoneal dialysis patient survival
- Kim H.; Ryu D.-R.
- Ewha Authors
- SCOPUS Author ID
- Issue Date
- Journal Title
- Kidney Research and Clinical Practice
- Kidney Research and Clinical Practice vol. 36, no. 1, pp. 22 - 28
- Cardiovascular diseases; Hemodialysis; Mortality; Peritoneal dialysis
- The Korean Society of Nephrology
- SCOPUS; KCI
- Document Type
- The number of patients with end-stage renal disease (ESRD) has rapidly increased, as has the cost of dialysis. Peritoneal dialysis (PD) is an established treatment for ESRD patients worldwide; it has a variety of advantages, including autonomy and flexibility, as well as economic benefits in many countries compared to hemodialysis (HD). However, the long-term survival rate of PD remains poor. Although direct comparison of survival rate between the dialysis modalities by randomized controlled trials is difficult due to the ethical issues, it has always been a crucial point when deciding which dialysis modality should be recommended to patients. Recently, in many countries, including the United States, Brazil, Spain, Australia, and New Zealand, the survival rate in PD patients has significantly improved. PD patient survival in Korea has also improved, but Korean PD patients are known to have higher risk of mortality and major adverse cardiovascular, cerebrovascular events than HD patients. Herein, we further evaluate why Korean PD patients had worse outcomes; we suggest that special attention should be paid to patients with diabetes, coronary artery disease, or congestive heart failure when they choose PD as the first dialysis modality in order to reduce mortality risk. © 2017 by The Korean Society of Nephrology.
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.